Previous close | 16.35 |
Open | 16.35 |
Bid | 5.00 |
Ask | 15.00 |
Strike | 700.00 |
Expiry date | 2025-12-19 |
Day's range | 16.35 - 16.35 |
Contract range | N/A |
Volume | |
Open interest | 264 |
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
HRMY vs. REGN: Which Stock Is the Better Value Option?